Skip to content
E2 · Observational studyCohortPEM unclearObservationalPeer-reviewed
Standard · 3 min

Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.

Cash, Alan, Kaufman, David Lyons

Journal of translational medicine2022DOIPubMed

Design
Observational
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

This study tested whether a supplement called oxaloacetate could help reduce fatigue in ME/CFS and Long COVID patients. Over 6 weeks, patients taking oxaloacetate showed significant improvements in both mental and physical fatigue—with ME/CFS patients improving by 22–33% depending on dose, and Long COVID patients improving by up to 47%—compared to expected placebo improvements of about 6%.

Why It Matters

With no FDA-approved treatments for ME/CFS fatigue and millions suffering from persistent post-COVID fatigue, this study offers preliminary evidence for a potential low-risk nutritional intervention. The dose-dependent response pattern and improvements substantially exceeding historical placebo suggest oxaloacetate warrants further rigorous investigation in this severely understudied patient population.

Observed Findings

What the study reports it measured.

  • ME/CFS patients receiving 500 mg BID showed 21.7% fatigue reduction; those receiving 1,000 mg BID showed 27.6% reduction; and those receiving 1,000 mg TID showed 33.3% reduction (dose-dependent response).
  • Long COVID patients showed fatigue reductions up to 46.8% over 6 weeks.
  • Both physical and mental fatigue components improved significantly in both patient populations compared to baseline (P < 0.005).
  • Improvement exceeded historical placebo control average of 5.9%.

Inferred Conclusions

What the authors interpret from those results.

  • Oxaloacetate may effectively reduce pathological fatigue in both ME/CFS and Long COVID patients, with higher doses associated with greater benefit.
  • The medication-like efficacy combined with its classification as a nutritional supplement suggests it could bridge an important treatment gap for millions of patients.
  • Further rigorous randomized controlled trials are warranted to confirm efficacy and establish optimal dosing.

Remaining Questions

  • Does oxaloacetate reduce fatigue through specific biological mechanisms (e.g., ATP production, mitochondrial function) or through placebo/expectancy effects in this open-label design?
  • What is the optimal effective dose, and does tolerability or safety change at higher doses over longer treatment periods?
  • Do improvements persist beyond 6 weeks, and are there responder/non-responder phenotypes based on ME/CFS disease duration, severity, or biomarkers?
  • How do results compare in a properly blinded, randomized controlled trial with concurrent placebo controls?

What This Study Does Not Prove

This study does not prove oxaloacetate is effective because it lacks a concurrent randomized control group receiving placebo in parallel—relying instead on historical placebo data introduces bias and cannot control for concurrent environmental or temporal factors. The open-label design is subject to placebo response and expectancy effects, and the study cannot establish whether oxaloacetate specifically alleviates fatigue through a biological mechanism or through other unmeasured factors.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Cash, Alan & Kaufman, David Lyons (2022). Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.. Journal of translational medicine. https://doi.org/10.1186/s12967-022-03488-3

BibTeX

@article{mecfsatlas-cash-2022-oxaloacetate-treatment,
  author  = {Cash, Alan and Kaufman, David Lyons},
  title   = {Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.},
  journal = {Journal of translational medicine},
  year    = {2022},
  doi     = {10.1186/s12967-022-03488-3},
  note    = {PubMed: 35764955},
  url     = {https://www.mecfsatlas.com/evidence/cash-2022-oxaloacetate-treatment},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-15. https://www.mecfsatlas.com/evidence/cash-2022-oxaloacetate-treatment

Contribute

Private, reviewed by a human. Not a public comment thread.